Citigroup maintains Veradermics at Buy, raises price target to $175 from $160

Citigroup kept its Buy rating on Veradermics and increased its price target to $175 from $160, suggesting a 21.6% upside from the Nov 9 close of $143.95. Recent analyst price targets for the company range from $150 to $204.

Original reporting
Published Nov 10, 2026, 7:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 7:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Citigroup maintains Veradermics at Buy, raises price target to $175 from $160 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The upgrade suggests potential upside but lacks fresh operational news, limiting immediate trading impact.

02

Market read

Analyst price target change provides modest new information for traders monitoring micro‑cap equities.

03

What to watch

No new fundamental data accompanies the target change; market reaction may be muted.

Relevance 5/10Novelty 6/10Timing: today

Background

Citi analyst raised the price target for Veradermics from $160 to $175, indicating a 9.4% increase.

Market effects

None

None

None

Counterpoint

Price target upgrades may be overly optimistic for a micro‑cap with limited liquidity.

Key entities

  • Veradermics

    Subject of the analyst price target upgrade.

Related articles

$MANEHighAI 9/10

Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics, Inc (MANE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Positive topline results from Phase 3 Study ‘304’ and positive 12-month data from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first ora

HighAI 8/10

Why is Veradermics stock climbing today?

Veradermics Inc (MANE) stock rose 2.5% after reporting positive 12-month data from its Phase 2/3 Study 302 for VDPHL01, showing hair growth in men with mild-to-moderate pattern hair loss. Leerink Partners raised its price target to $150 from $135. The company plans to announce data from a female pattern hair loss study in 2027. The S&P 500 also surged 1.7% on a strong jobs report.

$MANEMedAI 8/10

Veradermics stock rises on 12-month hair growth trial data

Veradermics Inc (NYSE:MANE) shares rose 2.3% after releasing 12-month Phase 2/3 trial data for VDPHL01, an oral minoxidil formulation. Twice-daily treatment showed a 43.9 hairs/cm2 increase, while once-daily showed 29.7 hairs/cm2. 89.1% of twice-daily participants reported visible hair coverage improvement. The treatment was well-tolerated with no serious adverse events.

$MANEHighAI 8/10

Veradermics Reports Positive 12-Month VDPHL01 Study Results in Male Hair Loss

Veradermics reported positive 12-month results for VDPHL01 in male hair loss, showing increased hair counts and improved coverage. Twice-daily dosing saw 43.9 hairs/cm² growth, while once-daily had 29.7. The treatment was well-tolerated with no serious adverse events. According to the company, crossover participants from placebo also showed improvements after six months.